Objective To investigate the effect and safety of Anlotinib combined with Camrelizumab in patients with ad-vanced non-small cell lung cancer and influence for prognostic markers.Methods 80 patients with advanced non-small cell lung cancer in Department of Tumor Ⅱ,Liaoyang Central Hospital from June 2019 to September 2022 were chosen as the study object,and they divided into control group(40 cases)and observation group(40 cases)by the random number table.The control group were treated with Anlotinib,the observation group were treated with Anlotinib combined with Cam-relizumab.The total effective rates,various toxic and side effects rates,tumor markers(carcinoma embryonic antigen[CEA],neuron-specific enolase[NSE]and cytokeratin 19 fragment antigen 21-1[Cyfra21-1])and prognostic markers(circulating tumor cell[CTC],neutrophil-to-lymphocyte ratio[NLR]and interleukin-8[IL-8])before and after the treatment of two groups were compared.Results The total effective rate of observation group was higher than that of control group,the differ-ence was statistically significant(P＜0.05),the various toxic and side effects rates of two groups were compared,the differ-ences were not statistically significant(P＞0.05),the tumor markers and prognostic markers of observation group at second and forth treatment cycles were lower than those of control group and before the treatment,the differences were statistically significant(P＜0.05).Conclusion The effect of Anlotinib combined with Camrelizumab in patients with advanced non-small cell lung cancer is better,its safety is worth recognition too,and it can significantly improve the expression of prognostic markers,so its application value in patients with advanced non-small cell lung cancer is higher.
维普
万方数据